glp-1 obesity drug news today october 23 2025 oct GLP-1 Drugs: 2025 Pulse Survey (U.S.) Indications for GLP-1/GIP RA Summary

this translated into a steadily increasing absolute risk difference over time, from 9.28 per 1000 people at one year to 19.25 per 1000 people at three years (supplementary table S13)

Furthermore, the data from a phase II study in participants with obesity and MASH presented at the American Diabetes Association showed those on survodutide achieved 18.7% mean weight loss after 46 weeks compared to the placebo group

GLP-1 dose conversion chart and safe switching guide Navigating GLP-1 agonist conversions requires more than a simple chart

If a recent evaluation was completed and appropriate follow-up scheduled, reexamination is not warranted

K.LiB.GraysonB

A review article in 2021 discussed the utility of GLP-1RA for the treatment of IIH, with a particular focus on weight management (5)